Browse drugs

… distinctive early induction profile suggests that low doses of BRG399 may effectively stimulate antitumor immune surveillance while m…

…2 on both the innate and adaptive immune systems.The ability of IMNN-001 to generate IL-12, IFN-γ and TNF-α locally and the induction of…

…elivery of genetic medicines.Following systemic administration, CLD-401 specifically homed to tumors and primed the tumor microenvironm…

…h evidence of biological and therapeutic activities.Conclusions JEN-101 was safe and biologically active in dogs with advanced melanoma…

…the experimental window following engraftment with human PBMCs. Tarlatamab (DLL3 TCE) and Talquetamab (GPRC5D TCE) were evaluated in NCG-M…

…nd amplified neurotrophic signaling with increased secretion of BDNF. Inhibition of NRP2 mitigated neurite extension and axonogenesi…

…e responses, underscoring the urgent need for novel strategies. Lurbinectedin, an approved second-line therapy for SCLC, is being evaluated i…

…rget effects and mechanistic insights.Results Perturbation with tripolide, doxorubicin, and cobimetinib resulted in dose dependent cell t…

…n = 4, other/unknown primary n = 17) from patients treated with ipilimumab 3mg/kg and nivolumab 1mg/kg at Thomas Jefferson University were…

…yopreserved BCMA-specific CAR-T from one lot were cultured with BCMA-loaded mimics and H929 cell line in 5 independent experiments, generat…

…backbone: PD-L1-EphA2-CD28 (dual 1), EphA2-PD-L1-CD28 (dual 2), PD-L1-EphA2-4-1BB (dual 3), and EphA2-PD-L1-4-1BB (dual 4). Constructs were trans…

…uring the first two rounds of serial challenge, compared to TCR(NLV)-primed and TCR(T8A)-primed TCR-CAR T cells. Consistently, CAR-…